HGH 191AA (3.33 mg Vial)

Research overview by Biohacking Elite · Last updated October 24, 2026
Research information notice

This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.

SINGLE PEPTIDES

HGH 191AA (3.33 mg Vial)

RESEARCH & EDUCATIONAL REFERENCE GUIDE

HGH 191AA is recombinant human growth hormone (somatropin) identical to endogenous GH, studied extensively for its effects on body composition, metabolism, and tissue repair[1][7]. Clinical protocols typically employ subcutaneous administration once daily to mimic physiological GH secretion patterns[2][3].

! For research and educational purposes only. Review all research information, limitations and references before interpretation.
NEUTRAL LABORATORY CALCULATIONS Use the Research Calculator for concentration, dilution and unit-conversion math. It does not provide or recommend a personal dose or administration schedule.
HGH 191AA (3.33 mg Vial)
01

Quick Reference

Alternate / Common Names
Somatropin; Recombinant human growth hormone
Classification
Recombinant 191-amino-acid human growth hormone (somatropin)
Vial / Reference Strength
3.33 mg (10 IU)
Product / Research Format
Lyophilized

What is HGH 191AA?

Research overview based on the cited scientific literature.

• Goal: Support increases in lean body mass, reductions in adipose tissue, and enhanced metabolic function[7][8].

• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Storage Instructions

Proper storage preserves peptide quality and bioactivity.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.

• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for several weeks when stored properly[5].

• Allow vials to reach room temperature before opening to reduce condensation uptake.

• Critical: Avoid freeze–thaw cycles of reconstituted peptide, as freezing can denature the protein[5].

How is HGH 191AA studied?

HGH 191AA is recombinant human growth hormone (somatropin) that is structurally identical to endogenous GH secreted by the pituitary gland[1][5]. Clinical studies demonstrate that GH administration promotes increases in lean body mass, reductions in adipose tissue, and improvements in body composition through multiple mechanisms including enhanced lipolysis, increased protein synthesis, and stimulation of IGF-1 production[7][8]. Pivotal research by Rudman and colleagues showed that six months of HGH administration in older men significantly increased lean body mass and decreased adipose mass compared to placebo[7]. Long-term follow-up studies in adults with GH deficiency have demonstrated sustained improvements in muscle strength and body composition with maintenance dosing[8].

Subcutaneous administration once daily, particularly at bedtime, is designed to mimic physiological patterns of endogenous GH secretion[2][3]. Dosing protocols vary based on therapeutic goals: conservative replacement protocols typically employ 150–500 mcg daily[1], while advanced metabolic and performance research protocols may utilize 1000–2000 mcg daily[4]. Higher doses produce more pronounced physiological effects but also carry increased risk of side effects including fluid retention, joint discomfort, and potential metabolic disturbances[2].

What does the research report about HGH 191AA?

Observations from clinical research literature.

Potential Benefits

• Increases in lean body mass and reductions in adipose tissue in clinical studies[7][8].

• Enhanced fat oxidation and lipolysis in dose-dependent manner[4].

• Sustained improvements in muscle strength and body composition with long-term use in GH-deficient adults[8].

• Improved metabolic parameters in appropriate clinical contexts[1][2].

Potential Side Effects

• Injection site reactions (redness, irritation); can be minimized by proper rotation technique[3].

• Fluid retention and peripheral edema, particularly at higher doses[2].

• Joint discomfort or arthralgias reported in some clinical protocols.

• Potential glucose metabolism effects; monitoring may be warranted in extended protocols[2].

• Risk of lipoatrophy at injection sites if rotation is inadequate[3].

Note: While research in healthy athletes showed GH increased lean body mass, it did not significantly improve muscle strength or exercise performance in systematic reviews[10]. Side effects and benefits are dose-dependent, with higher doses yielding more pronounced effects but also increased risk profiles.

Research Limitations / Risk Notes

Higher doses produce more pronounced physiological effects but also carry increased risk of side effects including fluid retention, joint discomfort, and potential metabolic disturbances[2]. While research in healthy athletes showed GH increased lean body mass, it did not significantly improve muscle strength or exercise performance in systematic reviews[10].

Important Note

This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.

References

Additional Research and Background

Scroll to Top